Carbohydrate-based whole cell cancer vaccines

Details Carbohydrate-based whole cell cancer vaccines Carbohydrate-based whole cell cancer vaccines

A - Human Necessities

61

K

A61K 39/00 (2006.01) A61P 35/00 (2006.01) C12N 5/06 (2006.01)

Patent

CA 2399325

When tumor cells are incubated with N-propionyl mannosamine, the N-acetyl groups of their surface .alpha.2-8 polysialic acid are converted to N- propionyl groups. The resultant bio-engineered cancer cells can be killed and used as a allogenic or autologous therapy or vaccine. The presence of N-propionylated polysialic acid-specific antibodies is detected in animals immunized with the vaccine prior to tumor implantation. Mice immunized with the heat-killed cancer cells experience better protection against challenge with live autologous RMA-S cells than mice immunized with heat-killed autologous RMA-S cells. Killed cells having modified sialic acid groups on their surface may be used as an anti-cancer therapy or vaccine either alone or in combination with an anti-cancer compound, such as cyclophosphamide.

Affiliated with

Also associated with

Rating

Carbohydrate-based whole cell cancer vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carbohydrate-based whole cell cancer vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbohydrate-based whole cell cancer vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1430243